Lumos Diagnostics Holdings Limited (LDXHF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $69.6M is the value of all shares combined. Beta 0.61: the stock has moved about 39% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerLumos Diagnostics Holdings Limited (LDXHF) trades at $0.0737. Lumos Diagnostics Holdings Limited develops and commercializes rapid point-of-care diagnostic tests, primarily focusing on infectious diseases. Market cap: $69.6M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for LDXHF: LDXHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LDXHF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
LDXHF: 1/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Lumos Diagnostics Holdings Limited (LDXHF) Healthcare & Pipeline Overview
Lumos Diagnostics Holdings Limited is an Australian contract research and development company specializing in point-of-care diagnostic tests. With a focus on infectious diseases, their product suite includes rapid tests for viral and bacterial respiratory infections, positioning them in the evolving landscape of decentralized diagnostics within the healthcare sector.
What Is the Investment Thesis for LDXHF?
Lumos Diagnostics Holdings Limited presents a speculative investment opportunity within the point-of-care diagnostics market. The company's focus on rapid infectious disease testing addresses a critical need for timely and accurate diagnoses. Key value drivers include the potential for increased adoption of FebriDx in reducing unnecessary antibiotic use and the expansion of ViraDx and CoviDx in managing respiratory infections. However, the company's negative profit margin of -75.8% and reliance on OTC markets present significant risks. Successful commercialization of their product pipeline and achieving profitability are crucial for long-term value creation. Investors should closely monitor revenue growth, cost management, and regulatory approvals.
Based on FMP financials and quantitative analysis
LDXHF Key Highlights
Market capitalization of $69.6M, reflecting its position as a smaller player in the diagnostics market.
- P/E ratio of -15.93, indicating that the company is currently unprofitable.
- Negative profit margin of -75.8%, highlighting the challenges in achieving profitability.
- Gross margin of 3.0%, suggesting limited pricing power and high cost of goods sold.
- Beta of 0.61, indicating lower volatility compared to the overall market.
Who Are LDXHF's Competitors?
LDXHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CORBF Global Cord Blood Corporation | $0.95 | 0.00% | $127M | — |
| ORXOF Orexo AB (publ) | $1.44 | 0.00% | $50.6M | — |
| PBIGF Paradigm Biopharmaceuticals Limited | $0.19 | 0.00% | $114M | — |
| PFGTF Pacific Edge Limited | $0.19 | 0.00% | $233M | — |
| SHIEF Shield Therapeutics plc | $0.09 | 0.00% | $91.6M | — |
| SERA Sera Prognostics, Inc. | $2.05 | +1.99% | $78.3M | — |
| DRIO DarioHealth Corp. | $6.90 | +4.86% | $50.5M | 335-pillar |
| PRPO Precipio, Inc. | $26.91 | +5.12% | $48.0M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LDXHF's Key Strengths?
Focus on rapid point-of-care diagnostics
- Portfolio of tests for infectious diseases
- Proprietary reader technology
- Established presence in the US and Australian markets
What Are LDXHF's Weaknesses?
Negative profit margin
- Limited financial resources
- Dependence on OTC market
- Small market capitalization
What Could Drive LDXHF Stock Higher?
Potential regulatory approvals for new diagnostic tests in key markets.
- Expansion of sales and marketing efforts to drive adoption of FebriDx and ViraDx.
- Strategic partnerships with pharmaceutical companies and healthcare providers.
- Positive clinical trial results for new diagnostic assays.
- Increasing demand for point-of-care testing solutions.
What Are the Key Risks for LDXHF?
Financial-distress signal — its Altman Z-Score of -2.10 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 6 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from established players in the diagnostics market.
- Regulatory hurdles and reimbursement challenges.
- Technological obsolescence and the emergence of new diagnostic technologies.
- Dependence on OTC market and limited financial resources.
- Negative profit margin and challenges in achieving profitability.
What Are the Growth Opportunities for LDXHF?
- Expansion of FebriDx adoption: FebriDx, Lumos Diagnostics' POC test for differentiating viral and bacterial respiratory infections, holds significant growth potential. With rising concerns about antibiotic resistance, broader adoption of FebriDx can reduce unnecessary antibiotic prescriptions. The market for rapid respiratory infection diagnostics is estimated to reach $5 billion by 2028, presenting a substantial opportunity for Lumos Diagnostics to capture market share through increased sales and marketing efforts.
- Commercialization of ViraDx: The ViraDx three-in-one POC test for influenza A, influenza B, and COVID-19 offers a convenient solution for managing respiratory infections. As the demand for multiplex testing increases, ViraDx can gain traction in various healthcare settings. The market for multiplex diagnostic assays is projected to grow at a CAGR of 8% over the next five years, driven by the need for efficient and comprehensive diagnostic solutions.
- Geographic expansion: Lumos Diagnostics currently focuses on the United States and Australia. Expanding into new geographic markets, such as Europe and Asia, can drive significant growth. The global point-of-care diagnostics market is expected to reach $40 billion by 2027, with emerging markets offering particularly attractive growth opportunities. Strategic partnerships and regulatory approvals will be crucial for successful geographic expansion.
- Development of new diagnostic tests: Investing in research and development to expand the product pipeline with new diagnostic tests can drive long-term growth. Focusing on emerging infectious diseases and unmet diagnostic needs can create new revenue streams. The market for novel diagnostic assays is characterized by high growth potential, driven by technological advancements and the need for innovative solutions.
- Strategic partnerships and collaborations: Collaborating with pharmaceutical companies, healthcare providers, and research institutions can accelerate the commercialization of Lumos Diagnostics' products and expand its market reach. Strategic partnerships can provide access to new technologies, distribution channels, and funding opportunities. The diagnostics industry is increasingly characterized by collaborations and partnerships aimed at driving innovation and market access.
What Are LDXHF's Competitive Advantages?
- Proprietary diagnostic technologies
- Established presence in the point-of-care testing market
- Focus on infectious disease diagnostics
What Does LDXHF Do?
Founded in 2004 and headquartered in Melbourne, Australia, Lumos Diagnostics Holdings Limited operates as a contract research and development company focused on the development and commercialization of rapid point-of-care (POC) diagnostic tests. The company's primary focus is on the diagnosis and management of infectious diseases, particularly in the United States and Australia. Lumos Diagnostics offers a range of products, including FebriDx, a POC diagnostic test designed to detect and differentiate between viral and bacterial respiratory infections. This test aids clinicians in making informed decisions regarding antibiotic prescriptions, addressing the critical issue of antibiotic resistance. Other products include ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19, and CoviDx, a rapid antigen test for COVID-19. These tests are designed for rapid results, enabling timely clinical decisions. In addition to diagnostic tests, Lumos Diagnostics provides desktop readers, disposable readers, and Lumos Leelu readers, which are integral to the functionality of their POC testing solutions. Lumos Diagnostics aims to improve patient outcomes and reduce healthcare costs by providing accurate and timely diagnostic information at the point of care.
What Products and Services Does LDXHF Offer?
- Develops rapid point-of-care (POC) diagnostic tests.
- Commercializes diagnostic tests, focusing on infectious diseases.
- Offers FebriDx, a POC test for differentiating viral and bacterial respiratory infections.
- Provides ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.
- Manufactures CoviDx, a rapid antigen test for COVID-19.
- Supplies desktop readers, disposable readers, and Lumos Leelu readers for test administration.
How Does LDXHF Make Money?
- Develops and manufactures rapid diagnostic tests.
- Sells diagnostic tests and associated reader devices to healthcare providers.
- Generates revenue through direct sales and distribution partnerships.
What Industry Does LDXHF Operate In?
Lumos Diagnostics operates within the medical diagnostics and research industry, a sector experiencing growth driven by increasing demand for rapid and point-of-care testing. The market is characterized by technological advancements, regulatory requirements, and intense competition. Companies like CORBF (Co-Diagnostics Inc.), ORXOF (Orasure Technologies Inc), PBIGF (Predictive Oncology Inc), PFGTF (Perma-Fix Environmental Services Inc), and SHIEF (Shin-Etsu Chemical Co. Ltd.) represent the competitive landscape. Lumos Diagnostics' focus on infectious disease diagnostics positions it within a segment driven by public health concerns and the need for efficient and accurate testing solutions.
Who Are LDXHF's Key Customers?
- Hospitals and clinics
- Physician offices
- Point-of-care testing centers
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 20 snapshots
| 2026-08-23 | 40 |
| 2026-08-27 | 40 |
| 2026-08-31 | 40 |
| 2026-09-04 | 40 |
| 2026-09-08 | 40 |
| 2026-09-11 | 40 |
What changed?
The score has stayed at 40.
Over the same 19 days the stock moved -7.9%.
Company Profile
Lumos Diagnostics Holdings Limited operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Carlsbad, US. The company is led by CEO Douglas Ward. LDXHF has traded publicly since 2021.
Key Financial Metrics
Return on assets is -44.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.73 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -16.7%, the inverse of the P/E and a quick read on earnings relative to price.
LDXHF Valuation & Market Position
With a $69.6M market cap, Lumos Diagnostics Holdings Limited sits in the micro-cap segment of the market.
Quarterly Financial Performance: Lumos Diagnostics Holdings Limited
Revenue for Lumos Diagnostics Holdings Limited came in at $7.2M during Q4 FY2026, a 16.1% improvement versus the preceding quarter. The company recorded a net loss of $71K, with diluted EPS of $0.00. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, LDXHF averaged $-0.00 in diluted EPS.
Financial Health
Lumos Diagnostics Holdings Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.10 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Lumos Diagnostics Holdings Limited has missed Wall Street's EPS estimate in 4 of its last 6 reported quarters — a mixed record worth weighing. Reported results have landed about 1219.2% below estimates on average.
LDXHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Focus on rapid point-of-care diagnostics
- Portfolio of tests for infectious diseases
- Proprietary reader technology
- Established presence in the US and Australian markets
Bear Case
- Negative profit margin
- Limited financial resources
- Dependence on OTC market
- Small market capitalization
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 FY2026 | $7M | -$70,898 | $0.0002 |
| Q2 FY2026 | $6M | -$5M | -$0.01 |
| Q4 FY2025 | $6M | -$2M | -$0.0020 |
| Q2 FY2025 | $6M | -$5M | -$0.01 |
Q4 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis
LDXHF Latest News
-
Nvidia Q2 earnings beat expectations with strong data center growth
proactiveinvestors.com · Aug 26, 2026
-
Lumos Diagnostics sets up US growth push after landmark year for FebriDx
Yahoo! Finance: LDXHF News · Aug 26, 2026
-
Lumos Diagnostics sets up US growth push after landmark year for FebriDx
Proactive · Aug 26, 2026
-
Lumos Diagnostics enters US commercial growth phase targeting a billion dollar opportunity
Proactive · Aug 5, 2026
LDXHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LDXHF.
Price Targets
Wall Street price target analysis for LDXHF.
LDXHF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LDXHF; grades run from A+ (80-100) to F (below 30).
Latest News
Nvidia Q2 earnings beat expectations with strong data center growth
Lumos Diagnostics sets up US growth push after landmark year for FebriDx
Lumos Diagnostics sets up US growth push after landmark year for FebriDx
Lumos Diagnostics enters US commercial growth phase targeting a billion dollar opportunity
Leadership: Douglas Ward
CEO
Douglas Ward serves as the CEO of Lumos Diagnostics Holdings Limited. His background includes extensive experience in the diagnostics and healthcare industries. Prior to joining Lumos Diagnostics, he held leadership positions at various medical device and biotechnology companies, where he focused on commercial strategy, product development, and market access. Ward's expertise spans across various therapeutic areas, including infectious diseases and oncology. He holds an MBA from a leading business school and a Bachelor's degree in Biomedical Engineering.
Track Record: Under Douglas Ward's leadership, Lumos Diagnostics has focused on expanding its product portfolio and commercial reach. Key milestones include the development and launch of ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19. Ward has also overseen strategic partnerships aimed at accelerating the commercialization of Lumos Diagnostics' products. His focus on innovation and market access has been instrumental in driving the company's growth.
LDXHF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Lumos Diagnostics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it challenging for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face less stringent regulatory oversight, increasing the risk of fraud and manipulation.
- OTC Tier: OTC Other
- Limited financial disclosure
- Higher risk of fraud and manipulation
- Lower liquidity
- Greater price volatility
- Less stringent regulatory oversight
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory approvals.
- Monitor news and press releases for any red flags.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC stocks.
- Established presence in the point-of-care testing market
- Portfolio of diagnostic tests for infectious diseases
- Proprietary reader technology
- Presence in US and Australian markets
LDXHF Healthcare Stock FAQ
Is LDXHF a good stock?
Stock Expert AI does not rate LDXHF buy, sell or hold. Lumos Diagnostics Holdings Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about LDXHF stock?
As of March 16, 2026, there is no readily available analyst consensus on LDXHF stock due to its OTC listing and limited coverage. Key valuation metrics, such as the P/E ratio of -15.93 and a negative profit margin of -75.8%, indicate that the company is currently unprofitable.
What are the key factors to evaluate for LDXHF?
Evaluate LDXHF on fundamentals, analyst consensus, and risk factors. However, the company's negative profit margin of -75.8% and reliance on OTC markets present significant risks. Not financial advice.
How frequently does LDXHF data refresh on this page?
LDXHF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven LDXHF's recent stock price performance?
Lumos Diagnostics Holdings Limited (LDXHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on rapid point-of-care diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LDXHF overvalued or undervalued right now?
Lumos Diagnostics Holdings Limited (LDXHF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of LDXHF?
Yes, most major brokerages offer fractional shares of Lumos Diagnostics Holdings Limited (LDXHF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track LDXHF's earnings and financial reports?
Lumos Diagnostics Holdings Limited (LDXHF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for LDXHF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.